At the end of 2015, the MCC approved the use of the combination of tenofovir and emtricitibine (Truvada®) for pre-exposure prophylaxis of HIV (PrEP). Taking the combination tablet daily has been shown to be safe and effective in lowering the risk of HIV transmission.

PrEP should be given to all people at risk of contracting HIV (e.g. those with a partner who is positive). It is vital to remember that a person’s risk – and therefore, need for PrEP – may change over time. It is also vital that the combination drug is not given mistakenly to people who are already HIV-positive, and regular HIV testing must be done. Renal function must be monitored, as tenofovir may affect the kidneys.

Use of PrEP, in combination with safer sex practices, is a great addition to our HIV prevention armamentarium.